APLT vs. PGEN, TNGX, CMRX, BTMD, SNDL, TRVI, YMAB, VYGR, IMMP, and ITOS
Should you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include Precigen (PGEN), Tango Therapeutics (TNGX), Chimerix (CMRX), biote (BTMD), SNDL (SNDL), Trevi Therapeutics (TRVI), Y-mAbs Therapeutics (YMAB), Voyager Therapeutics (VYGR), Immutep (IMMP), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry.
Applied Therapeutics vs.
Precigen (NASDAQ:PGEN) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability.
Precigen received 355 more outperform votes than Applied Therapeutics when rated by MarketBeat users. Likewise, 67.34% of users gave Precigen an outperform vote while only 57.55% of users gave Applied Therapeutics an outperform vote.
Precigen presently has a consensus price target of $6.33, indicating a potential upside of 470.57%. Applied Therapeutics has a consensus price target of $6.10, indicating a potential upside of 834.15%. Given Applied Therapeutics' higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than Precigen.
Precigen has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500.
33.5% of Precigen shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 44.9% of Precigen shares are owned by company insiders. Comparatively, 8.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Applied Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -3,521.68%. Precigen's return on equity of -123.06% beat Applied Therapeutics' return on equity.
Precigen has higher earnings, but lower revenue than Applied Therapeutics. Precigen is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Applied Therapeutics had 22 more articles in the media than Precigen. MarketBeat recorded 29 mentions for Applied Therapeutics and 7 mentions for Precigen. Precigen's average media sentiment score of 0.32 beat Applied Therapeutics' score of 0.06 indicating that Precigen is being referred to more favorably in the media.
Summary
Precigen beats Applied Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Applied Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Applied Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APLT) was last updated on 1/20/2025 by MarketBeat.com Staff
